On Monday we learnt from Sir Patrick Vallance, the government’s Chief Scientific Adviser that Coronavirus will possibly under no circumstances disappear and a vaccine won’t stop it completely. He also mentioned that ministers and authorities really should quit ‘over-promising’ and be realistic about the prospects of a vaccine and the likely timeline of one, unlikely ahead of spring next year.
He then echoed his earlier warnings and those of his colleague Professor Chris Whitty that the COVID-19 fight will be a extended one, and it will be with us for good.
So, from this ought to we assume there is no ‘silver bullet’ for COVID-19 infections?
What if there were a single remedy that:
could cease the infection in its tracks,
was anti-inflammatory controlling the immune system’s response to the infection and stopping it from overreacting dangerously,
in situations exactly where sufferers developed secondary bacterial infections in the lungs could supercharge antibiotics boosting their efficacy and eve,
was a repurposed drug currently confirmed as protected
was quick to make, scalable at the level essential to make a distinction in the pandemic and was price successful, then would not that be anything we really should all be having excited about?
Surely even though no such ‘silver bullet’ game changing therapy exists? Right after all, the only treatments we hear about for COVID are those which President Trump took, which had been either extremely new, pricey and experimental or have a extremely narrow application to a unique aspect of the disease.
Effectively, you heard it right here very first – such a ‘silver bullet’ remedy does exist these days. It really is referred to as Nylexa®, from the small UK biotech business NovaBiotics Ltd. It really is active components have been safely used in medicines that treat unrelated conditions for over 30 years.
NovaBiotics discovered Nylexa’s prospective advantages in COVID-19 following a decade of study in tough to treat, drug-resistant infections, which includes the complicated chest infections and inflammation linked with cystic fibrosis (CF) lung disease. In March they applied for a £1m grant from Innovate UK (representing the government) to start out clinical studies. That grant was sooner or later awarded earlier this month, and the government are now contemplating whether or not or not to include things like Nylexa on two separate NHS platform research.
But why, I hear you ask, if this is so very good have we not heard about it prior to? Why are the government and the press not shouting about this from the rooftops? Why is this not getting demanded by clinicians desperate for effective treatments for their patients?
centerforcovidcontrol.org ‘m afraid to say, it all boils down to income. Tiny biotech corporations uncover it challenging to get consideration as they do not have the resources accessible to their larger much better funded rivals. The names we study about regularly when it comes to ground breaking new therapies are invariably big multi-national pharmaceutical businesses with deep pockets and major budgets to market their own specific wares. They make certain their drugs get the essential focus. NovaBiotics is a tiny private corporation funded by a group of loyal and supportive shareholders so sadly do not have the resources to compete for interest with the major boys.
Which is why this situation is so frustrating. In mitigating the overall health consequences of contracting COVID-19, Nylexa® could boost public self-confidence of living with the virus for the longer term and potentially permit a higher degree of normality to return to the way in which we live, benefiting the economy straight in addition to easing COVID-19’s burden on the NHS and healthcare systems globally. Yet finding individuals in positions of influence to take notice amongst all the other people competing for their focus is quite tough certainly.
It is reported that there are thousands of prospective COVID-19 treatments in clinical trials across the planet. I would challenge any individual to show me one which has the very same prospective for optimistic influence as Nylexa®, however this is not at the moment aspect of any trial, in spite of its impeccable credentials. So come on UK Government, and ministers, get your finger out and get this drug into trials instantly. The sooner it gets tested, the sooner it can be made use of to assist sort out the mess the pandemic has brought on to all our lives.
About NovaBiotics Ltd
NovaBiotics Ltd is a clinical-stage biotechnology corporation focused on the design and style and development of very first-in-class therapies for hard-to-treat, medically unmet infectiousdiseases caused by bacteria and fungi and respiratory situations such as cystic fibrosis and COVID-19.
A major innovator in the anti-infectives space, the Company’s robust technologies and small business model has been validated by means of productive development, from concept to late stage clinical improvement, of its most advanced item candidates. In addition to the lead Nylexa® programme and the Company’s other late-stage assets (Lynovex® for cystic fibrosis, NP213/Novexatin® for onychomycosis), NovaBiotics has generated a robust pipeline of earlier stage, higher-worth drug candidates like NP339 (Division of Overall health and Social Care funded programme) for life threatening, drug resistant invasive fungal disease and NP432 for multi- drug resistant bacterial infections.